-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion to Present Phase 1 Results for Oral GLP-1 Drug BMF-650 at ObesityWeek 2026

PUBT·11/10/2026 12:08:59
Listen to the news
Biomea Fusion to Present Phase 1 Results for Oral GLP-1 Drug BMF-650 at ObesityWeek 2026
  • Biomea Fusion will present Phase 1 results for BMF-650 at ObesityWeek on Nov. 16, 2026, in National Harbor, Maryland.
  • The first-in-human study evaluated an investigational oral small-molecule GLP-1 receptor agonist within its diabetes and obesity pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874065) on November 10, 2026, and is solely responsible for the information contained therein.